Formulation Development
Spring Bank Announces New Clinical Collaboration With Roche
Spring Bank Pharmaceuticals, Inc. recently announced a new clinical collaboration with Roche to explore the co-administration of SB 11285, Spring Bank's intravenously (IV)-administered STING (STimulator…
Perrigo & Catalent Announce FDA Approval
Perrigo Company plc and its partner Catalent Pharma Solutions recently announced the US FDA has approved Perrigo’s abbreviated new drug application for generic albuterol sulfate…
FDA Grants IND Approval to Promising Anti-Cancer Agent
Noxopharm recently announced the US FDA has approved the Investigational New Drug (IND) application for Veyonda for combination treatment with doxorubicin in patients with soft…
Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Firm
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health recently announced…..
Purdue Receives NIH Grant to Treat Antibiotic-Resistant Lower Respiratory Infections
A Purdue team has received a $3.2-million grant from the National Institutes of Health for its work to treat antibiotic-resistant lower respiratory infections – the fourth-leading cause of…
Saama & Pfizer to Transform Work of Clinical Data Managers & Monitors With AI
Saama Technologies, Inc. recently announced it signed an agreement with Pfizer Inc. to develop and deploy an AI-powered analytics solution to reduce the….
Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation
Cue Biopharma, Inc. recently announced the company’s therapeutic Immuno-STAT (Selective Targeting and Alteration of T cells) platform is scheduled to be featured in a Merck…
leon & Nucleus Medical Announce Collaboration to Develop & Manufacture Novel Transplantation Medicine
This license agreement enables Nucleus to utilize proprietary MicroJet Reactor (MJR) nanotechnology to improve stability, increase solubility and enhance bioavailability of its lead asset in…
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
Aravive, Inc. recently announced that the independent Data Monitoring Committtee (DMC) has reviewed the open-label data following the first 28-day treatment cycle for the three…
Mustang Bio Announces First Subject Treated in Phase 1/2 Trial
Mustang Bio, Inc. recently announced that the first subject treated with the optimized MB-106 (CD20-targeted, autologous CAR T cell therapy) manufacturing process, developed in collaboration…
Diasome Announces Positive Results from Phase 2 OPTI-1 Study
Diasome Pharmaceuticals, Inc. recently announced positive results from its Phase 2 OPTI-1 study of injectable hepatocyte directed vesicle (HDV) added to mealtime insulin in people with…
Annovis Issued Patent for Method of Treating Parkinson’s Disease & Other Lewy Body Diseases
Annovis Bio Inc. was recently issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinson’s disease, Lewy body dementia, and other…
TriSalus Life Sciences & Roger Williams Medical Center Announce Initiation of Phase 1 Clinical Trial for a Novel Delivery Technology
TriSalus Life Sciences recently announced the initiation of a new clinical trial assessing the safety and feasibility of an innovative new treatment that combines its…..
Alkahest Announces Initiation of Phase 2b Clinical Trial
Alkahest, Inc. recently announced the initiation of a Phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first….
Cocrystal Pharma's Structure-Based Technology Demonstrated Broad Utility
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics using its proprietary structure-based drug discovery platform technology to create first-and…
Oculis Announces Positive OCS-01 Phase 2 Data
Oculis S.A. recently reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment…
Zumutor Biologics & Catalent Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors
Catalent recently announced it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Zumutor…
BeyondSpring’s Plinabulin Stimulates Both the Adaptive & Innate Immune System
BeyondSpring Inc. recently announced that new clinical data on the company’s first-in-class, late-stage asset, Plinabulin, shows its ability to potently stimulate the innate immune system.…
Biologics Patent Expiry Trend Expected to Have Positive Impact
Expectations for biosimilars are high in 2020, and the drug class will finally begin to make its mark in the US, says GlobalData, a leading…